儿童外伤性眼内炎致伤原因50例临床分析

目的 分析儿童外伤性眼内炎致伤原因。方法 回顾分析1998年10月-2004年10月本科收治的50例儿童外伤性眼内炎致伤原因。结果 在各类致伤物中以废弃的一次性注射器针头比例最大。结论 预防儿童外伤性眼内炎，应严格加强废弃的一次性注射器的回收管理。     

儿童外伤性眼内炎

目的 分析３１例儿童外伤性眼内炎的临床特点。方法 回顾性对儿童外伤性眼内炎的致伤物、年龄、就诊时间、临床表现及治疗结果进行讨论。结果 多见于学齿前儿童的自伤,目前致伤物为废弃的一次性注射针头的病例明显增多,占６５．６％。对于就诊迟,视功能损害重的病例,虽经积极的手术治疗便预后极差。结论 对于儿童外伤性眼内炎重在预防,早期诊治是挽救一定的视功能的关键。     

玻璃体切割术治疗儿童外伤性眼内炎

目的:探讨玻璃体切割术治疗儿童外伤性眼内炎的手术时机和疗效。方法:对103例(103眼)儿童外伤性眼内炎的致伤原因、致伤物、就诊时间、临床表现、治疗方式及效果进行回顾性分析。结果:眼内炎103眼(100%)控制,保存了眼球,86眼(83·5%)视力不同程度的提高,9眼(8.7%)视力无变化,8眼(7.8%)视力降低。结论:玻璃体切除术联合敏感抗生素的应用是治疗儿童外伤性眼内炎的有效手段。     

儿童外伤性眼内炎致伤原因分析(附50例)

目的：分析儿童外伤性眼内炎致伤原因，方法：回顾分析1996年10月－2000年10月本科收治的儿童外伤性眼内炎。结果：在各类致伤物中以废弃的一次性注射器针头比例最高，结论：预防儿童外伤性眼内炎，应严格加强废弃的一次性注射器的回收管理。     

儿童外伤性眼内炎玻璃体切割手术的治疗效果及影响因素分析

目的　分析儿童外伤性眼内炎玻璃体切割手术后的治疗效果及影响因素。方法　对 1 7例(1 7眼 )儿童外伤性眼内炎的致伤原因、致伤物、性别、年龄、就诊时间、临床表现、治疗方式及效果进行回顾性分析。结果　 1 7例患儿中因延迟就诊 ,病情进展为全眼球炎而行眼内容物剜除术 3例 ,1 4例急诊行玻璃体切割术。术后随访 3～ 6月 ,视力 0 3与 0 7各 1例 ,0 0 2～ 0 0 5者 3例 ,光感～0 0 2者 9例 ;玻璃体切割术后发生低眼压 4例 ,占 2 8 5 %。结论　儿童外伤性眼内炎玻璃体切割手术后治疗效果与眼内炎的程度、就诊是否及时、致病菌毒力大小有关。术后发生低眼压的原因可能与炎症形成睫状体膜、前部增生性玻璃体视网膜病变及硅油填充有关。     

一次性注射器致眼球穿通伤的临床分析

本文报道了４９例儿童眼球穿通伤的致伤原因、临床表现、治疗结果和预后。致伤原因中主要为玩耍废弃的一次性注射器时针头刺伤，少数为缝衣针刺伤和植物性针刺致伤。受伤后１８．４％发生外伤性白内障，７３．５％发生化脓性眼内炎，只发生角膜穿通伤者仅占８．２％。经治疗后６３．３％的患者视力低于０．０５，３０．６％的患者眼球萎缩。后果严重，应引起医院管理工作者的注意。     

儿童外伤性眼内炎的手术治疗

目的 探讨玻璃体切除术治疗儿童外伤性眼内炎的疗效.方法 回顾性研究,17例(17眼)儿童外伤性眼内炎治疗方法及疗效.结果 单纯玻璃体腔注药控制4眼;玻璃体切除13眼,其中玻璃体、晶状体切除联合硅油填充10眼,玻璃体切除联合硅油填充2眼,眼内注气1眼;17眼中共保留晶状体5眼.9眼视力提高(52.94％),视力不变者3眼(17.65％),视力下降5眼(29.41％)(其中3眼眼球萎缩).结论 儿童外伤性眼内炎手术效果与眼内炎程度、就诊时间、致病菌毒力有关,无外伤性白内障的眼内炎玻璃体切除是否保留晶状体要考虑年龄及眼内炎的严重程度.     

玻璃体切割治疗儿童外伤性眼内炎

在儿童眼外伤中,以外伤性眼内炎最为严重,因病原菌随致伤物直接进入眼内,对眼内组织结构造成严重破坏,如不及时治疗,往往因炎症难以控制,而导致视力丧失,眼球摘除或自行萎缩.现将笔者1996～2000年收治的20例20眼外伤性眼内炎报告如下.     

38例儿童外伤性眼内炎临床分析

眼内炎是一种凶险的感染性化脓性眼病，眼外伤是引起眼内炎的常见原因之一，常见于眼球穿孔伤、眼球破裂伤和眼内异物，如不治疗，其致盲率极高，达78％。现对我院5a间38例儿童外伤性眼内炎的有关临床资料进行回顾性分析，旨在探讨不同治疗时机和方法对该病疗效的影响。     

儿童外伤感染性眼内炎40例临床分析

眼内炎是眼科常见的眼内严重感染疾患,可致严重后果。由于儿童的年龄、性格及活动特点,故儿童外伤感染性眼内炎的致伤原因、治疗及预后均有许多特点。本文总结了４０例因儿童外伤致眼内炎的治疗情况。１资料与方法１．１临床资料本文统计了自１９９６年１月至１９９８年...     

A case of cystoid macular edema treated by intravitreal triamcinolone in a patient with systemic lupus erythematosis

We describe the use of intravitreal triamcinolone in the treatment of macular edema associated with systematic lupus erythematosus providing short-term resolution of cystoid macular edema and increase in visual acuity. No side effects from the injection have been seen as yet. We suggest this treatment to be considered in patients for whom laser treatment may be inappropriate or not feasible, or even as an alternative/safer option for all patients.     

A new method of treatment of retinitis pigmentosa/pigmentary abiotrophy

We report our results of treatment of pigmentary retinal abiotrophy with a drug known in the Soviet Union as Encad. Repeated courses of treatment twice a year for four to 14 years stabilized the pathologic process in more than 60% of 467 treated patients. We provide details of the treatment and specific indications and contraindications.     

Therapy of chorioretinitis presumed to be caused by histoplasmosis.

We acknowledge that for most patients with istoplasmic chorioretinitis, the only treatment available is steroids. We agree with Schlaegel that steroids have to be used in adequate doses and for long periods of time. Alternate-day treatment should be instituted as soon as possible. Because it takes the adrenals 10 days to to weeks to be suppressed by sterid therapy, we treat our patients with daily doses for as short a time as possible and then witch over o alernate-day treatment. A short-acting steroid such as prednisone, prednisolone, or methylprednisolone should be used at the outset if long-term therapy is necessary and one anticipates using alternate-day therapy...     

Visual function improvement in patients with macroprolactinomas treated with bromocriptine

We studied eight patients who had visual field defects secondary to prolactin-secreting macroadenomas and who had improved visual function with bromocriptine treatment without surgery or radiation. We recommend bromocriptine as a primary treatment for prolactin-secreting macroadenomas. If therapy is effective, continued regular neuro-ophthalmologic, endocrine, and imaging studies are necessary, because treatment with bromocriptine must be continued indefinitely.     

Oculomotor nerve schwannoma: case series and literature review

Oculomotor nerve schwannomas are rare benign cranial nerve tumors. There are only a limited number of reports on this pathology in the literature, and there are currently no established management guidelines that aid providers in deciding on surgical versus nonsurgical management. We assess the published literature on the topic to identify indications for treatment as well as outcome measures (e.g., local control rates, survival rates, and complication rates) that have been reported as associated with the various treatment modalities. We attempt to develop an algorithm for evaluation and treatment of oculomotor nerve schwannomas in order to establish consensus on how these tumors should be treated.     

Intravenous acyclovir treatment for extensive herpetic keratitis in a liver transplant patient

Herpetic infection is a common complication among immune suppressed patients following heart, kidney and bone marrow transplantations,in leukemia patients, in AIDS patients, and during treatment with cytotoxic drugs. In the cases described in the literature, oral acyclovir was recommended as a treatment for the acute infection, as well as for prophylaxis. Intravenous acyclovir is not a routine treatment for herpetic keratitis, but is recommended for cases of insufficient clinical response to oral treatment, and defective absorption of acyclovir by the gastrointestinal tract. We present a patient who underwent 4 liver transplantations,was treated regularly with immunosuppressive drugs, and who developed extensive herpetic keratitits. The keratitis was resistant to both topical ointment and oral acyclovir treatment. Recovery was only achieved following the intravenous administration of acyclovir. We recommend intravenous acyclovir treatment at avery early stage for immune suppressed patients with extensive herpes simplex keratitis. This revised version was published online in July 2006 with corrections to the Cover Date.     

Yellow mercuric oxide: a treatment of choice for phthiriasis palpebrarum.

Thirty-five patients presenting with phthiriasis palpebrarum were all treated with a regimen of 1% yellow oxide of mercury ointment four times daily for 14 days. At the conclusion of treatment there was complete resolution of the signs and symptoms of the disease. No side effects due to the treatment were reported or detected. We have shown that 1% mercuric oxide ointment is both a safe and effective treatment for phthiriasis palpebrarum. We recommend it as the treatment of choice.     

Ethambutol Chiasmal Toxicity with Bitemporal Hemianopia

Ethambutol is a well recognized antimicrobial agent used as a first line agent in the treatment of tuberculosis. Optic neuropathy is a known complication of ethambutol therapy. Rarely, chiasmal ethambutol toxicity may manifest as a bitemporal visual field deficit. We report an additional case of ethambutol chiasmal toxicity with a bitemporal hemianopia. We also include a review of the medical literature on clinical presentation, pathophysiology, monitoring parameters, treatment, and prognosis of ethambutol toxicity.     

Blepharitis and the collagen eye patch

In our practice, blepharitis is one of the more common eyelid abnormalities and one of the most difficult to treat. We introduce a new treatment that we have found to be helpful. A prospective study was devised to test its efficacy using 20 patients distributed randomly into three different treatment protocols. Our new protocol, using lyophilized collagen pads as adjunctive treatment, significantly improved results compared with controls. We had a 79% improvement in symptomatology and a 78% improvement in objective findings.     

Corneal intra-epithelial neoplasia (CIN). Treatment by combined excision and antimetabolite therapy

CASE REPORT: We present two clinical cases of corneal intra-epithelial neoplasia defined histopathologically. DISCUSSION: We sought to establish the importance of treatment with Mitomycin-C in two cases of corneal intra-epithelial neoplasia. The differential diagnosis was established based on the evolutionary character of the process, as well as specific histopathological aspects of these entities. In both cases, treatment with Mitomycin-C before, during and after surgery contributed to the decrease in the size of the lesion and to their cure without relapse.